Glycemic control, therapy trends, and diabetes complications, were evaluated in LANDMARC, a prospective observational 3-year study (CTRI/2017/05/008452), of participants with T2D on ≥2 antihyperglycemic medications. This subgroup analysis of 52 sites from East India (Kolkata, Northeast) included 843 participants (mean [SD] baseline [BL] age: 53.1 [9.5] years, T2D duration: 8.7 [6.0] years and A1C: 7.9% [1.7]). At BL, most were insulin-naïve (n=647; 76.7%), mainly on OADs (n=644; 76.4%). At 3 years, 422 (57.5%) participants were on OADs only, while 295 (40.2%) were on insulin + OADs. Biguanides was the most prescribed drug class (BL: 793 [94.1%] and 3-years: 681 [92.8%]). Basal insulin usage increased from BL (n=99; 11.7%) to 3 years (n=213; 29.0%). The mean (SD) A1C, FPG, and PPG decreased by 1.0 (1.6) %, 23.4 (52.9) mg/dL, and 39.2 (82.6) mg/dL, respectively. East India had the highest proportion (53.1%; n=303) of participants with A1C<7% at 3 years. CV death and neuropathy were most common macro and microvascular complications, respectively (Table). Hypertension and dyslipidemia were the most common CV risk factors. An understanding of regional trends in glycemia, therapy, and complications may help strategize future diabetes management practices in India.
N. Rais: None. S. Chowdhury: None. S. Kalra: Speaker's Bureau; Abbott, Bayer Inc., Novo Nordisk, Sanofi. S. Mukharjee: None. T. Chaudhury: None. S. Das: None. D. Saha: None. S.K. Shah: None. S. Bhattacharyya: None. S.K. Menon: Employee; Sanofi. A. Gadekar: None. D. Chodankar: Employee; Sanofi.
Sanofi
